Nascent Australian Firm SpeeDx Seeks Licensees, Partners for 'MNAzyme' Tech
April 01, 2010
Nascent Australian Firm SpeeDx Seeks Licensees, Partners for 'MNAzyme' Tech
SpeeDx, a spinout of Johnson & Johnson's Australian research subsidiary, claims its multi-component nucleic acid enzymes, or MNAzymes, provide significant advantages over current enzymes for multiplex qPCR applications.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Australia's SpeeDx Demonstrates Multiplexed MNAzyme qPCR; Looks to Move Tech to MDx Market
December 20, 2012 / PCR Insider - Universal Biosensors Licenses SpeeDx's MNAzyme Tech for Point-of-Care MDx Apps
September 22, 2011 / PCR Insider - IP Watch: BioFire Diagnostics, SpeeDx, IntegenX, Life Technologies, Stanford Among US Patent Winners
March 14, 2013 / PCR Insider - Product Watch: Bioline's Isolate II NA Purification Kits; SciGene's Hyb-Ice Thermal Profiler
February 7, 2013 / PCR Insider - Meridian Bioscience Reports 13 Percent Spike in Q1 Revenues Driven by Growth in Illumigene Products
January 24, 2013 / PCR Insider